This research explores (PGM, Co(III)) heterobimetallic complexes as a targeted alternative to traditional Pt(II) therapies like cisplatin, which are often limited by systemic toxicity and drug resistance. The study specifically evaluates KN1 (DTBC), an iron-chelating ligand, and KNK 0.1 (Co(tren)DTBC), a cobalt-based prodrug designed for selective activation. Using two-way ANOVA for data analysis, the drugs were tested against the MCF-7 breast cancer cell line across 24-hour and 72-hour intervals under both normoxic and hypoxic conditions. Results indicated that while KN1 exhibits moderate cytotoxicity, KNK 0.1 effectively functions as a hypoxia-activated anticancer prodrug, releasing its cytotoxic payload specifically in oxygen-deficient environments. Ultimately, this work demonstrates the potential of cobalt-containing complexes to improve tumor selectivity and reduce the side effects typically associated with conventional chemotherapy.